Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Omer Karrar; Maymona Abdelmagid; Masooma Rana; Moazah Iftikhar; Kristen McCullough; Aref Al-Kali; Hassan B. Alkhateeb; Kebede H. Begna; Michelle A. Elliott; Abhishek Mangaonkar; Antoine Saliba; Mehrdad Hefazi Torghabeh; Mark R. Litzow; William Hogan; Mithun Shah; Mrinal M. Patnaik; Animesh Pardanani; Talha Badar; Hemant Murthy; James Foran; Jeanne Palmer; Lisa Sproat; Nandita Khera; Cecilia Arana Yi; Ayalew Tefferi; Naseema Gangat

doi:10.1002/ajh.27180

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek Mangaonkar, Antoine Saliba, Mehrdad Hefazi Torghabeh, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James ForanJeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E63-E66
Journal	American journal of hematology
Volume	99
Issue number	2
DOIs	https://doi.org/10.1002/ajh.27180
State	Published - Feb 2024

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.27180

Cite this

Karrar, O., Abdelmagid, M., Rana, M., Iftikhar, M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Elliott, M. A., Mangaonkar, A., Saliba, A., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., ... Gangat, N. (2024). Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. American journal of hematology, 99(2), E63-E66. https://doi.org/10.1002/ajh.27180

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. / Karrar, Omer; Abdelmagid, Maymona; Rana, Masooma et al.
In: American journal of hematology, Vol. 99, No. 2, 02.2024, p. E63-E66.

Research output: Contribution to journal › Letter › peer-review

Karrar, O, Abdelmagid, M, Rana, M, Iftikhar, M, McCullough, K, Al-Kali, A, Alkhateeb, HB, Begna, KH, Elliott, MA, Mangaonkar, A, Saliba, A, Hefazi Torghabeh, M, Litzow, MR , Hogan, W, Shah, M, Patnaik, MM , Pardanani, A, Badar, T, Murthy, H, Foran, J , Palmer, J , Sproat, L , Khera, N, Arana Yi, C, Tefferi, A & Gangat, N 2024, 'Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival', American journal of hematology, vol. 99, no. 2, pp. E63-E66. https://doi.org/10.1002/ajh.27180

@article{250dad1a64a347e5a251aaf9e7fb9b99,

title = "Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival",

author = "Omer Karrar and Maymona Abdelmagid and Masooma Rana and Moazah Iftikhar and Kristen McCullough and Aref Al-Kali and Alkhateeb, {Hassan B.} and Begna, {Kebede H.} and Elliott, {Michelle A.} and Abhishek Mangaonkar and Antoine Saliba and {Hefazi Torghabeh}, Mehrdad and Litzow, {Mark R.} and William Hogan and Mithun Shah and Patnaik, {Mrinal M.} and Animesh Pardanani and Talha Badar and Hemant Murthy and James Foran and Jeanne Palmer and Lisa Sproat and Nandita Khera and {Arana Yi}, Cecilia and Ayalew Tefferi and Naseema Gangat",

year = "2024",

month = feb,

doi = "10.1002/ajh.27180",

language = "English (US)",

volume = "99",

pages = "E63--E66",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia

T2 - Comparative analysis of response, toxicity, and survival

AU - Karrar, Omer

AU - Abdelmagid, Maymona

AU - Rana, Masooma

AU - Iftikhar, Moazah

AU - McCullough, Kristen

AU - Al-Kali, Aref

AU - Alkhateeb, Hassan B.

AU - Begna, Kebede H.

AU - Elliott, Michelle A.

AU - Mangaonkar, Abhishek

AU - Saliba, Antoine

AU - Hefazi Torghabeh, Mehrdad

AU - Litzow, Mark R.

AU - Hogan, William

AU - Shah, Mithun

AU - Patnaik, Mrinal M.

AU - Pardanani, Animesh

AU - Badar, Talha

AU - Murthy, Hemant

AU - Foran, James

AU - Palmer, Jeanne

AU - Sproat, Lisa

AU - Khera, Nandita

AU - Arana Yi, Cecilia

AU - Tefferi, Ayalew

AU - Gangat, Naseema

PY - 2024/2

Y1 - 2024/2

UR - http://www.scopus.com/inward/record.url?scp=85179683425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85179683425&partnerID=8YFLogxK

U2 - 10.1002/ajh.27180

DO - 10.1002/ajh.27180

M3 - Letter

C2 - 38100217

AN - SCOPUS:85179683425

SN - 0361-8609

VL - 99

SP - E63-E66

JO - American journal of hematology

JF - American journal of hematology

IS - 2

ER -

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this